Detalles de la búsqueda
1.
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study.
Haematologica
; 103(8): 1298-1307, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29773593
2.
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
Am J Hematol
; 90(9): 755-68, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26040495
3.
Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Oncologist
; 19(4): 346-7, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24674873
4.
Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Oncologist
; 19(4): 348-9, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24674874
5.
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.
Leukemia
; 34(8): 2125-2137, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32572189
6.
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
J Clin Oncol
; 36(3): 231-237, 2018 01 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-29091516
7.
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
J Clin Oncol
; 23(23): 5314-22, 2005 Aug 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-15955899
8.
Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors.
Clin Cancer Res
; 18(4): 1092-100, 2012 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22179664
9.
Response to Miller et al: resistant mutations in CML and Ph(+) ALL - role of ponatinib.
Biologics
; 9: 23-4, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25733805
Resultados
1 -
9
de 9
1
Próxima >
>>